We are learning more about a stock sale by Pfizer CEO Albert Bourla on Monday, the same day the company announced its early vaccine trial results. We’ve seen certain circumstances like this before. That’s right… so remember, of course, Pfizer reported that 90 percent efficacy number on its vaccine trial on Monday. Its stock went up quite a bit. We’re now learning that Pfizer CEO Albert Bourla sold 5.6 million dollars worth of stock, 132,500 shares, on November 9th.
Menu
5 Responses
same old story “they” make money on the backs of US citizens…..always finding a way…..peek n sneak, pack n stack
is that considered “inside trading?”
looks like somebody knows something we don’t know.maybe he knows the vaccine is garbage an is getting out before it tanks,as far as the CEO not knowing how well a drug is doing in trials,this woman is an idiot,of course he knows,it’s his job to know.oh wait,the company is developing a new vaccine that could mean billions in sales,i think i’ll just ignore everything about it,what a baffoon!
But he didn’t sell all his stock, which says he wanted to make money but he still wants in.
Oh please, they totally know what’s about to happen once people start dying from this vaccine…
they sell it to make more shares available to the public because they anticipate a large buy out. In any case, the vax-makers all ensured they had our govt issue these ‘big pharma’ companies protection from lawsuits for failed CCP vaccine. They know the excipients are toxic and manifest problems that worsen over time but won’t be seen as cancers and neurological disorders for years for most patients.